EuropeSECountry Report

Psychedelic Research and Access in

Sweden

Blossom currently tracks 8 psychedelic clinical trials connected to Sweden, including 1 active study. The country page also links to 12 stakeholders and 1 event, giving the page ecosystem context beyond registered studies.

Ask Blossom about this country

Data updated

Key Insights

A concise view of the policy, research, access, and stakeholder details shaping psychedelic medicine inSweden.

  • 1

    Blossom tracks 8 psychedelic clinical trials connected to Sweden, including 1 active study.

  • 2

    Visible trial compounds include Esketamine, Ketamine and Psilocybin.

  • 3

    Visible trial topics include Treatment-Resistant Depression (TRD), Major Depressive Disorder (MDD) and Depressive Disorders.

  • 4

    The country page links to 12 stakeholders and 1 event in Blossom's ecosystem data.

  • 5

    The country access guide currently classifies access as "Medical Only (Private)"; details vary by compound and care setting.

Research and Access Snapshot

Blossom currently tracks 8 psychedelic clinical trials connected to Sweden, including 2 active studies.

Active trials
2

Currently active studies

Total trials
8

Linked to this country

Stakeholders
15

Linked organisations

Events
1

Linked events

Top Compounds

  • Esketamine(4)
  • Ketamine(2)
  • Psilocybin(2)

Top Study Topics

  • Treatment-Resistant Depression (TRD)(4)
  • Major Depressive Disorder (MDD)(3)
  • Depressive Disorders(1)

Active Trial Preview

View all trials →

Medical Access

Sweden maintains a restrictive narcotics framework: classical and novel psychedelics (psilocybin, MDMA, DMT, mescaline and most tryptamines) are controlled and have no routine medical/reimbursed use outside approved clinical research. Esketamine (Spravato) is authorised in the EU and has been the subject of Swedish health-economics assessment; access is limited to specialist psychiatry with supervised administration and regional/clinic-level funding decisions. Ketamine is an authorised anaesthetic and used in Swedish clinical research and some...

View trials→View stakeholders→View events→Open access guide→

Regulatory Status

The linked medical access and reimbursement guide summarises Sweden as "Medical Only (Private)". Sweden maintains a restrictive narcotics framework: classical and novel psychedelics (psilocybin, MDMA, DMT, mescaline and most tryptamines) are controlled and have no routine medical/reimbursed use outside approved clinical research. Esketamine (Spravato) is authorised in the EU and has been the subject of Swedish health-economics assessment; access is limited to specialist psychiatry with supervised administration and regional/clinic-level funding decisions.

Country Details

Region
Europe
Last updated
4 May 2026

Country Report

Medical Only (Private)

Medical Access

Sweden maintains a restrictive narcotics framework: classical and novel psychedelics (psilocybin, MDMA, DMT, mescaline and most tryptamines) are controlled and have no routine medical/reimbursed use outside approved clinical research. Esketamine (Spravato) is authorised in the EU and has been the...

Open access guide →

Pro Scorecard

Country Scorecard

Compare evidence, access, payment, delivery, local ecosystem, and review confidence for Sweden.

Open scorecard →

Road to Access Resources

Cost-effectiveness model

A reusable cost-utility, cost-effectiveness, and cost-benefit engine for psychedelic-assisted therapy, with illustrative parameter packs, evidence-status labels, and country HTA lenses.

Browse all resources →
All Countries→Clinical Trials→Stakeholders→Events→Country Scorecard→Research Papers→

Research Events in Sweden

Conferences, trainings, and research gatherings connected to the country report.

View all events →